Towards policies that capture the expected value of biomolecular diversity for drug discovery, human health, and well-being

Biologia Futura - Tập 72 - Trang 119-125 - 2020
Milica Pesic1,2, Dilfuza Egamberdieva1,3, Bartlomiej Kolodziejczyk1,4, Simon J. Elsässer1,5, Vidushi S. Neergheen1,6, Alexander Kagansky1,7
1‘Biodiversity for Survival via Biomedicine’ Working Group, Global Young Academy, Halle (Saale), Germany
2Institute for Biological Research, “Siniša Stanković”- National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia
3Faculty of Biology, National University of Uzbekistan, Tashkent, Uzbekistan
4Department of Pedagogical, Curricular and Professional Studies, University of Gothenburg, Gothenburg, Sweden
5Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
6Department of Health Sciences, Faculty of Science and Centre for Biomedical and Biomaterials Research, University of Mauritius, Réduit, Republic of Mauritius
7Centre for Genomic and Regenerative Medicine, School of Biomedicine, Far Eastern Federal University, Vladivostok, Russian Federation

Tóm tắt

This paper aims to help policy makers with a characterization of the intrinsic value of biodiversity and its role as a critical foundation for sustainable development, human health, and well-being. Our objective is to highlight the urgent need to overcome economic, disciplinary, national, cultural, and regional barriers, in order to work out innovative measures to create a sustainable future and prevent the mutual extinction of humans and other species. We emphasize the pervasive neglect paid to the cross-dependency of planetary health, the health of individual human beings and other species. It is critical that social and natural sciences are taken into account as key contributors to forming policies related to biodiversity, conservation, and health management. We are reaching the target date of Nagoya treaty signatories to have accomplished measures to prevent biodiversity loss, providing a unique opportunity for policy makers to make necessary adjustments and refocus targets for the next decade. We propose recommendations for policy makers to explore novel avenues to halt the accelerated global loss of biodiversity. Beyond the critical ecological functions biodiversity performs, its enormous untapped the repertoire of natural molecular diversity is needed for solving accelerating global healthcare challenges.

Tài liệu tham khảo

Council of the European Union (2011) EU Biodiversity Strategy to 2020-Council conclusions 32:1–6 Fabricant DS, Farnsworth NR, Fabricant DS, Farnsworth NR (2001) The value of plants used in traditional medicine for drug discovery. Environ Health Perspect 109:69–75 Gómez-Castro B, Kipper R (2019) Nagoya protocol on access and benefit-sharing. Microbiol Aust 40:103–106 Neergheen-Bhujun V et al (2017) Biodiversity, drug discovery, and the future of global health: introducing the biodiversity to biomedicine consortium, a call to action. J Glob Health 7:1–5 Scheffers BR, Joppa LN, Pimm SL, Laurance WF (2012) What we know and don’t know about Earth’s missing biodiversity. Trends Ecol Evol 27:501–510 Schöbel B, Pollmann W (1980) Further characterization of a chlorogenic acid hydrolase from aspergillus niger. Z Nat Sect C J Biosci 35:699–701 Zinsstag J, Schelling E, Waltner-Toews D, Tanner M (2011) From ‘one medicine’ to ‘one health’ and systemic approaches to health and well-being. Prev Vet Med 101:148–156